H2RAs vs. PPIs: Which Acid Reducer is Right for You?
Published: Nov 20, 2023
Medically reviewed by Alan Lucks | MD, Alan Lucks MDPC Private Practice - New York on November 20th, 2023.
Choosing the right medication to manage GERD can be confusing. Learn about the differences between H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) to find out which might work best for you.
Contents
Understanding H2 Receptor Antagonists
H2 receptor antagonists (H2RAs) work by decreasing the secretion of stomach acid. They are typically used for mild GERD symptoms and have a slower onset but longer action than antacids. However, their effectiveness may decrease over time due to tachyphylaxis. H2RAs are more effective than antacids but less potent than PPIs for severe GERD or esophagitis.
Proton Pump Inhibitors Explained
Proton pump inhibitors (PPIs) are the most potent acid reducers, working by blocking the hydrogen-potassium pump in stomach cells. They provide faster relief and are more effective than H2RAs, especially for frequent or severe symptoms. PPIs should be taken regularly rather than on demand to maintain their benefits. Despite their effectiveness, PPIs are more expensive and can have side effects.
Choosing the Right Option
The choice between H2RAs and PPIs depends on the severity and frequency of your GERD symptoms. For mild, occasional symptoms, H2RAs may suffice. For more severe or frequent symptoms, PPIs are usually recommended. Consider discussing with your doctor to determine which medication aligns best with your needs and lifestyle.
Frequently Asked Questions
H2RAs are used for mild GERD symptoms and have longer action than antacids.
PPIs block acid production in stomach cells, providing potent relief.
PPIs are stronger and more effective than H2RAs.
PPIs are generally safe but can have side effects and are more costly.
Key Takeaways
Which acid reducer will you choose to manage your GERD symptoms?
Talk with Doctronic to explore the best treatment options tailored for you.Related Articles
References
Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999; 94:92.
Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; :CD002095.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic. Always discuss health information with your healthcare provider.